Exploratory secondary analysis of the phase 3 DUO-E trial in 575 patients with mismatch repair proficient endometrial cancer: PFS hazard ratios favoured durvalumab and durvalumab plus olaparib over chemotherapy alone across most biomarker and histology subgroups.
Secondary analysisn = 575
Westin et al. Biomarker heterogeneity and efficacy of durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib in patients with mismatch repair proficient endometrial cancer: exploratory analyses of the DUO-E/GOG-3041/ENGOT-EN10 trial